Literature DB >> 33414392

A genome-wide methylation study reveals X chromosome and childhood trauma methylation alterations associated with borderline personality disorder.

María J Arranz1,2, Cristina Gallego-Fabrega1,3, Ana Martín-Blanco2,4,5, Joaquim Soler2,4,5, Matilde Elices2,4,5, Elisabet Dominguez-Clavé4, Juliana Salazar6, Daniel Vega5,7, Laia Briones-Buixassa7, Juan Carlos Pascual8,9,10.   

Abstract

Borderline personality disorder (BPD) is a severe and highly prevalent psychiatric disorder, more common in females than in males and with notable differences in presentation between genders. Recent studies have shown that epigenetic modifications such as DNA methylation may modulate gene × environment interactions and impact on neurodevelopment. We conducted an epigenome wide study (Illumina Infinium HumanMethylation450k beadchip) in a group of BPD patients with (N = 49) and without (N = 47) childhood traumas and in a control group (N = 44). Results were confirmed in a replication cohort (N = 293 BPD patients and N = 114 controls) using EpiTYPER assays. Differentially methylated CpG sites were observed in several genes and intragenic regions in the X chromosome (PQBP1, ZNF41, RPL10, cg07810091 and cg24395855) and in chromosome 6 (TAP2). BPD patients showed significantly lower methylation levels in these CpG sites than healthy controls. These differences seemed to be increased by the existence of childhood trauma. Comparisons between BPD patients with childhood trauma and patients and controls without revealed significant differences in four genes (POU5F1, GGT6, TNFRSF13C and FAM113B), none of them in the X chromosome. Gene set enrichment analyses revealed that epigenetic alterations were more frequently found in genes controlling oestrogen regulation, neurogenesis and cell differentiation. These results suggest that epigenetic alterations in the X chromosome and oestrogen-regulation genes may contribute to the development of BPD and explain the differences in presentation between genders. Furthermore, childhood trauma events may modulate the magnitude of the epigenetic alterations contributing to BPD.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33414392      PMCID: PMC7791113          DOI: 10.1038/s41398-020-01139-z

Source DB:  PubMed          Journal:  Transl Psychiatry        ISSN: 2158-3188            Impact factor:   6.222


  59 in total

1.  Increased DNA methylation of neuropsychiatric genes occurs in borderline personality disorder.

Authors:  Gerhard Dammann; Stefanie Teschler; Tanja Haag; Franziska Altmüller; Frederik Tuczek; Reinhard H Dammann
Journal:  Epigenetics       Date:  2011-12       Impact factor: 4.528

2.  Molecular signatures database (MSigDB) 3.0.

Authors:  Arthur Liberzon; Aravind Subramanian; Reid Pinchback; Helga Thorvaldsdóttir; Pablo Tamayo; Jill P Mesirov
Journal:  Bioinformatics       Date:  2011-05-05       Impact factor: 6.937

3.  Childhood maltreatment and methylation of the glucocorticoid receptor gene NR3C1 in bipolar disorder.

Authors:  Nader Perroud; Alexandre Dayer; Camille Piguet; Audrey Nallet; Sophie Favre; Alain Malafosse; Jean-Michel Aubry
Journal:  Br J Psychiatry       Date:  2013-06-06       Impact factor: 9.319

Review 4.  First Korean Case of Renpenning Syndrome with Novel Mutation in PQBP1 Diagnosed by Targeted Exome Sequencing, and Literature Review.

Authors:  Hye-In Jeong; Aram Yang; Jinsup Kim; Ja-Hyun Jang; Sung Yoon Cho; Dong-Kyu Jin
Journal:  Ann Clin Lab Sci       Date:  2018-07       Impact factor: 1.256

Review 5.  Epidemiology of borderline personality disorder.

Authors:  T A Widiger; M M Weissman
Journal:  Hosp Community Psychiatry       Date:  1991-10

6.  Traumatic stress and accelerated DNA methylation age: A meta-analysis.

Authors:  Erika J Wolf; Hannah Maniates; Nicole Nugent; Adam X Maihofer; Don Armstrong; Andrew Ratanatharathorn; Allison E Ashley-Koch; Melanie Garrett; Nathan A Kimbrel; Adriana Lori; Allison E Aiello; Dewleen G Baker; Jean C Beckham; Marco P Boks; Sandro Galea; Elbert Geuze; Michael A Hauser; Ronald C Kessler; Karestan C Koenen; Mark W Miller; Kerry J Ressler; Victoria Risbrough; Bart P F Rutten; Murray B Stein; Robert J Ursano; Eric Vermetten; Christiaan H Vinkers; Monica Uddin; Alicia K Smith; Caroline M Nievergelt; Mark W Logue
Journal:  Psychoneuroendocrinology       Date:  2017-12-27       Impact factor: 4.905

Review 7.  A biosocial developmental model of borderline personality: Elaborating and extending Linehan's theory.

Authors:  Sheila E Crowell; Theodore P Beauchaine; Marsha M Linehan
Journal:  Psychol Bull       Date:  2009-05       Impact factor: 17.737

8.  Childhood maltreatment and methylation of FK506 binding protein 5 gene (FKBP5).

Authors:  Audrey R Tyrka; Kathryn K Ridout; Stephanie H Parade; Alison Paquette; Carmen J Marsit; Ronald Seifer
Journal:  Dev Psychopathol       Date:  2015-11

9.  Proteomics-Metabolomics Combined Approach Identifies Peroxidasin as a Protector against Metabolic and Oxidative Stress in Prostate Cancer.

Authors:  Jodi Dougan; Ohuod Hawsawi; Liza J Burton; Gabrielle Edwards; Kia Jones; Jin Zou; Peri Nagappan; Guangdi Wang; Qiang Zhang; Alira Danaher; Nathan Bowen; Cimona Hinton; Valerie A Odero-Marah
Journal:  Int J Mol Sci       Date:  2019-06-21       Impact factor: 5.923

10.  Genome-wide DNA methylation comparison between live human brain and peripheral tissues within individuals.

Authors:  Patricia R Braun; Shizhong Han; Benjamin Hing; Yasunori Nagahama; Lindsey N Gaul; Jonathan T Heinzman; Andrew J Grossbach; Liesl Close; Brian J Dlouhy; Matthew A Howard; Hiroto Kawasaki; James B Potash; Gen Shinozaki
Journal:  Transl Psychiatry       Date:  2019-01-31       Impact factor: 6.222

View more
  1 in total

Review 1.  Can epigenetics shine a light on the biological pathways underlying major mental disorders?

Authors:  Luis Alameda; Giulia Trotta; Harriet Quigley; Victoria Rodriguez; Romayne Gadelrab; Daniella Dwir; Emma Dempster; Chloe C Y Wong; Marta Di Forti
Journal:  Psychol Med       Date:  2022-02-23       Impact factor: 10.592

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.